R&D expenditures increased by 26% in the first half of the year!

Event comments:

On August 24, Yasheng Pharmaceutical announced its 2021 interim financial report

Core varieties are coming to market soon

Yasheng’s core product HQP1351 (oribatinib) is used to treat patients with drug-resistant chronic myelogenous leukemia (CML)

In addition, this variety has also obtained the U.

From the perspective of international market experience, Novartis developed imatinib (trade name Gleevec) is the world’s first targeted BCR-ABL tyrosine kinase inhibitor (TKI) to be used as a treatment for chronic myeloid leukemia The first-line medication of CML can make the 10-year survival rate of CML patients reach 85%-90%

Benefiting from the development of BCR-ABL TKI, CML has almost become a chronic disease, and patients have been taking medication for a long time.

According to statistics, the incidence of CML accounts for 15% of all adult leukemia patients, and the global annual incidence rate is 1.

R&D: Enriching the pipeline and internationalization of innovative drug R&D pipelines

As of June 30, 2021, the research and development status of Yasheng Pharmaceutical's product pipelines and existing product pipelines are as follows:

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world

At present, Yasheng Pharmaceutical has established a rich pipeline of 8 new class 1 small molecule drug products entering the clinical stage, including inhibitors that inhibit key proteins in the apoptosis pathway such as Bcl-2, IAP or MDM2-p53; a new generation of cancer Inhibitors of kinase mutants appearing in treatment, etc.

During the reporting period, Yasheng Pharmaceutical had 144 authorized patents and more than 510 patent applications worldwide, of which about 110 patents have been authorized overseas

Commercialization: Amplify the commercial value of core products

For an innovative drug company that is about to enter the commercialization stage, the commercialization capability after the transformation of R&D results reflects the growth of the company's value curve

Judging from the information disclosed in Yasheng Pharmaceutical's Interim Report, the company is accelerating the listing process of its core candidate product HQP1351, and through its strong alliance with Cinda Biological, the commercial value of the company's product pipeline is expanded in an all-round way

It is understood that Cinda Bio has a broad coverage of commercial channels and a commercialization team of more than 2,000 people covering multi-field projects including sales, medical affairs, strategic planning and operations

From a market perspective, as a specific drug for the treatment of chronic myelogenous leukemia (CML) with T315I mutation, according to forecasts, the Chinese CML drug market faced by HQP1351 is expected to grow to 14.

In addition, APG and Cinda Biopharmaceuticals have also launched clinical cooperation and joint development on certain indications for APG-2575, anti-CD20 monoclonal antibody dalbervat, and anti-CD47 monoclonal antibody letaplimab (IBI88), indicating that domestic biopharmaceutical counterparts Sheng Medicine’s apoptosis pipeline clinical products are fully recognized

At this year’s ASCO meeting, Ascent Pharmaceuticals announced the first human trial of APG-2575 in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other hematological malignancies The latest data